FDA actions in brief
Thalidomide (Thalomid, Celgene) was approved in combination with dexamethasone for the treatment of patients with newly diagnosed multiple myeloma.
Thalidomide (Thalomid, Celgene) was approved in combination with dexamethasone for the treatment of patients with newly diagnosed multiple myeloma.
FDA approved 2 higher dose formulations of valsartan/hydrochlorothiazide (Diovan HCT, Novartis) for the treatment of hypertension. The combination tablets will now be available in 320/12.5 mg and 320/25 mg doses.
FDA approved infliximab (Remicade, Centocor) to treat children aged 6 to 17 years with active Crohn's disease.
FDA Clears Phase 2 Trial of Cannabis in PTSD
November 20th 2024After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More
